Navigation Links
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Date:5/8/2008

New imaging modality highlights Volcano commitment to intravascular imaging

and opens up new clinical and research applications

SAN DIEGO and BRUSSELS, Belgium, May 8 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the first human procedure using the Volcano OCT Imaging catheter. The procedure was performed by Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano OCT will complement its existing line of IVUS imaging catheters and pressure guidewires used for coronary imaging and lesion assessment.

Volcano acquired the OCT technology through its purchase of CardioSpectra at the end of 2007.

Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Volcano is committed to being the leader in intravascular imaging, both to complement everyday PCI technique, and to further the understanding of atherosclerotic disease progression. Our investment in this OCT product line underscores that commitment, and opens a series of new clinical applications and opportunities to complement our existing product line. We are delighted to be underway with our OCT effort just four months after completing the acquisition.

"With our two imaging technologies, we are the leader in intravascular imaging and commercializing this technology will provide us further competitive advantages. We are working on offerings that incorporate OCT functionality into our s5i IVUS platform, as well as standalone OCT systems. Our emph
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... of study data in small cell cervical ... using Caris Molecular Intelligence®, the company,s panomic, ... certain gene mutations which may explain sensitivities ... found that identification of certain biomarkers may ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received FDA ... adult men and women with androgenic alopecia (AGA) having ... IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... and under-deliver, FDA Clearance underscores the safety and efficacy ... than 80 million men and women who suffer with ...
(Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... has adopted a prearranged trading plan in accordance with ... , Chairman and CEO of Neogen Corporation, is a ... Neogen Corporation common stock. Herbert does not ... was appropriate. The filing is only for a portion ...
(Date:3/27/2015)... , March 27, 2015 Working ... Free Hospital in London , Richmond Pharmacology ... a global Phase 3 study for an investigational RNAi therapeutic ... orphan disease affecting the nerves and heart. ... Detail Based at St Georges University of ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... device company, today announced unaudited interim and ... and year ended,December 31, 2007. The unaudited ... potential adjustment as described under the section ...
... million to $360 million, WARSAW, Ind., Feb. 14 ... provider of products to the global orthopedic,device industry and ... of $79.1 million. The Company stated that,additional financial results ... previously announced on October 4, 2007, the Company,s Audit,Committee ...
... Experience in Biopharmaceutical Manufacturing, Engineering, Technical Services and ... ... 14 Laureate Pharma, Inc., a,full-service biopharmaceutical development and protein production ... In this newly created position, Mr. Swan will be responsible,for leading ...
Cached Biology Technology:Angiotech announces results for the fourth quarter ended December 31, 2007 2Angiotech announces results for the fourth quarter ended December 31, 2007 3Angiotech announces results for the fourth quarter ended December 31, 2007 4Angiotech announces results for the fourth quarter ended December 31, 2007 5Angiotech announces results for the fourth quarter ended December 31, 2007 6Angiotech announces results for the fourth quarter ended December 31, 2007 7Angiotech announces results for the fourth quarter ended December 31, 2007 8Angiotech announces results for the fourth quarter ended December 31, 2007 9Angiotech announces results for the fourth quarter ended December 31, 2007 10Angiotech announces results for the fourth quarter ended December 31, 2007 11Angiotech announces results for the fourth quarter ended December 31, 2007 12Angiotech announces results for the fourth quarter ended December 31, 2007 13Angiotech announces results for the fourth quarter ended December 31, 2007 14Angiotech announces results for the fourth quarter ended December 31, 2007 15Angiotech announces results for the fourth quarter ended December 31, 2007 16Angiotech announces results for the fourth quarter ended December 31, 2007 17Angiotech announces results for the fourth quarter ended December 31, 2007 18Angiotech announces results for the fourth quarter ended December 31, 2007 19Angiotech announces results for the fourth quarter ended December 31, 2007 20Angiotech announces results for the fourth quarter ended December 31, 2007 21Angiotech announces results for the fourth quarter ended December 31, 2007 22Angiotech announces results for the fourth quarter ended December 31, 2007 23Angiotech announces results for the fourth quarter ended December 31, 2007 24Symmetry Medical Reports Preliminary Fourth Quarter Revenue 2Symmetry Medical Reports Preliminary Fourth Quarter Revenue 3Symmetry Medical Reports Preliminary Fourth Quarter Revenue 4Laureate Pharma Appoints Gary Swan as Vice President of Operations 2
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Case Western Reserve University have found a way to create ... the developing heart in an animal model a key ... begun testing the technology to uncover how alcohol, drugs and ... in newborn humans. Passing blood cells drag on ...
... to rice cultivation built in the middle basin of the ... various migratory dabbling duck species to significantly increase in number ... that Vegas Altas del Guadiana is turned into a new ... populations are in decline and the loss of natural wetland ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
Cached Biology News:Finding triggers of birth defects in an embryo heart 2Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3